More Stories

Informist, Friday, Jan. 23, 2026

 

Please click here to read all liners published on this story

--Cipla Oct-Dec consol net profit INR 6.76 bln
--Analysts saw Cipla Oct-Dec consol net profit at INR 12.42 bln
--Cipla Oct-Dec consol revenue INR 70.74 bln
--Analysts saw Cipla Oct-Dec consol revenue at INR 74.65 bln
--Cipla Oct-Dec consol net profit INR 6.76 bln vs INR 15.71 bln year ago
--Cipla Oct-Dec net profit includes one-time cost INR 2.76 bln
--Cipla Oct-Dec profit excluding exceptional cost INR 9.52 bln
--Cipla Apr-Dec consol net profit INR 33.25 bln vs INR 40.51 bln year ago
--Cipla Oct-Dec consol revenue INR 70.74 bln vs INR 70.73 bln year ago
--Cipla Apr-Dec consol revenue INR 216.21 bln vs INR 208.18 bln year ago
--Cipla Q3 one-time cost INR 2.76 bln for new labour code implementation
--Cipla Q3 consol expenses INR 61.12 bln vs INR 53.78 bln yr ago, up 14% YoY
--Cipla Oct-Dec consol pharma revenue INR 67.46 bln vs INR 67.78 bln yr ago
--Cipla Q3 consol new venture sales INR 3.81 bln vs INR 3.41 bln yr ago
--Cipla shares fall, at INR 1,347.80, down 2% now vs flat earlier
--Cipla Oct-Dec consol EBITDA INR 12.55 bln vs INR 19.89 bln year ago
--Cipla Oct-Dec consol EBITDA down 36.9% on year
--Cipla Oct-Dec consol EBITDA margin 17.7% vs 28.1% year ago
--Cipla Oct-Dec India sales INR 34.57 bln, up 10% on year
--Cipla Oct-Dec North America sales INR 14.85 bln, down 22% on year
--Cipla Oct-Dec One Africa sales INR 10.01 bln, up 3% on year
--Cipla Oct-Dec consol R&D expense INR 4.94 bln, up 37.4% on year
--Cipla Oct-Dec consol R&D expense INR 4.94 bln, 7% of sales
--Cipla Oct-Dec North America sales $167 mln vs $226 mln year ago
--Cipla: Expect to launch 4 respiratory products in North America by FY27
--Cipla: Expect to launch 4 peptide products in North America by FY27
--Cipla: Revlimid had a small contribution in US revenue in Oct-Dec
--Cipla: Upcoming launches likely to cushion decline in Revlimid sales
--Cipla: Planning 4 respiratory Launches by FY27 in US, including Advair
--Cipla: Planning 4 peptide launches by FY27 in US, including Liraglutide

 

By Narayana Krishna

 

HYDERABAD – Cipla Ltd. Friday reported a consolidated net profit of INR 6.76 billion for the December quarter, down 57% on year, significantly lower than the Street estimates. This was the sharpest fall in net profit in the last 41 quarters. The company's revenue for the quarter was largely unchanged on-year to INR 70.7 billion but below the Street estimates.

 

Analysts had expected Cipla's December quarter net profit at INR 12.42 billion on a revenue of INR 74.65 billion. On quarter-on-quarter basis, the net profit was down nearly 50% and revenue down nearly 7%.

 

The company's North America sales declined 22% on year to INR 14.85 billion, a key reason for the company's weak performance.  

 

The company reported INR 2.76 billion of exceptional costs related to the implementation of new labour codes. Excluding this one-time impact, the net profit for the December quarter is at INR 9.52, Cipla said.

 

The company's core North America sales witnessed a significant fall, as the contribution from the generic cancer drug Revlimid declined for the quarter. In dollar terms, the company's North America sales were at $167 million against $226 million a year ago. Revlimid has a very small contribution for the quarter, Cipla said. The company achieved a 22% market share for its asthma drug Albuterol. The company is expecting that the upcoming launches are likely to fill the gap of Revlimid sales fall, Cipla said.

 

Cipla is also planning to launch four respiratory products and four peptide products in North America in 2026-27 (Apr-Mar). In the respiratory category, generic Advair is going to be the key drug for the company among FY27 launches. In the peptide segments, Liraglutide is one of the key launches.

 

Cipla's One India sales for the December quarter were up by 10% on-year to INR 34.57 billion, led by key therapies such as respiratory, urology, cardiac, and anti-diabetes, Cipla said. Chronic therapy share in overall India sales improved to 62.3%, the company said. The trade generics and consumer health segments also contributed to the overall sales in India, the company said.

 

In One Africa segment, the company sales rose 3% on year to INR 10.01 billion. The secondary market in this segment is up by 6.3% while the prescription business maintained its number two spot, Cipla said.

 

Cipla reported its December quarter pharma revenue of INR 67.46 billion against 67.78 billion a year ago. The new venture sales for the quarter were INR 3.81 billion against INR 3.41 billion a year ago.

 

As the contribution from Revlimid declined and US sales weakened, Cipla's December quarter earnings before interest, tax, depreciation, and amortisation margin fell sharply by over 1,000 basis points to 17.7%. The consolidated EBITDA for the quarter declined by nearly 37% on-year to INR 12.55 billion against the 19.89 billion. Analysts' estimates for Cipla's December quarter EBITDA is at INR 17.6 billion.

 

The company's December quarter total expenses were up nearly 14% on year to INR 61.12 billion. The company's spending on research and development for the quarter was up by 37.4% on year to INR 4.94 billion, 7% of the total sales. The employee benefit expenses for the quarter were up 10.6% on year to INR 13.2 billion.

 

Cipla's consolidated net profit for Apr-Dec fell 18% on year to INR 33.25 billion, while revenue was up by nearly 4% on year to INR 216.2 billion.

 

At 1448 IST, Cipla Ltd. shares were trading at INR 1306.60, down nearly 5% on the National Stock Exchange. End

 

US$1 = INR 91.96

IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT

 

Edited by Akul Nishant Akhoury

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.